
Fulgent Genetics FLGT
€ 14.57
2.31%
Quartalsbericht 2025-Q3
hinzugefügt 07.11.2025
Fulgent Genetics Langfristiger Schuldenstrom 2011-2026 | FLGT
Langfristiger Schuldenstrom Jährlich Fulgent Genetics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.44 M | 3.96 M | 6.13 M | 1.84 M | 267 K | 420 K | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 6.13 M | 267 K | 2.34 M |
Langfristiger Schuldenstrom anderer Aktien in der Diagnostik & Forschung
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
2.18 M | - | -6.23 % | $ 30.6 M | ||
|
Biodesix
BDSX
|
719 K | $ 15.07 | 2.1 % | $ 1.95 B | ||
|
Aspira Women's Health
AWH
|
202 K | - | -6.19 % | $ 10.5 M | ||
|
Co-Diagnostics
CODX
|
662 K | $ 4.4 | 101.83 % | $ 5.85 M | ||
|
Check-Cap Ltd.
CHEK
|
264 K | - | - | $ 9.42 M | ||
|
Castle Biosciences
CSTL
|
1.66 M | $ 24.84 | -0.84 % | $ 690 M | ||
|
DarioHealth Corp.
DRIO
|
430 K | $ 8.4 | 3.7 % | $ 33.5 M | ||
|
BioNano Genomics
BNGO
|
697 K | $ 1.2 | 0.84 % | $ 6.53 M | ||
|
Akumin
AKU
|
17.2 M | - | -17.87 % | $ 25.9 M | ||
|
Charles River Laboratories International
CRL
|
57.7 M | $ 173.89 | -0.58 % | $ 8.62 B | ||
|
Accelerate Diagnostics
AXDX
|
829 K | - | -61.36 % | $ 2.46 M | ||
|
DexCom
DXCM
|
21.6 M | $ 62.22 | -0.24 % | $ 24.3 B | ||
|
Biomerica
BMRA
|
358 K | $ 2.17 | -0.91 % | $ 4.98 M | ||
|
Global Cord Blood Corporation
CO
|
147 K | - | - | $ 399 M | ||
|
Celcuity
CELC
|
54 K | $ 112.63 | -0.27 % | $ 5.27 B | ||
|
Genetic Technologies Limited
GENE
|
264 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
21.5 M | - | 0.12 % | $ 80.1 M | ||
|
Exact Sciences Corporation
EXAS
|
33.6 M | - | - | $ 19.8 B | ||
|
DermTech
DMTK
|
3.07 M | - | -11.32 % | $ 2.94 M | ||
|
Quest Diagnostics Incorporated
DGX
|
174 M | $ 198.02 | 0.17 % | $ 22 B | ||
|
Guardant Health
GH
|
27.7 M | $ 93.83 | 2.94 % | $ 11.8 B | ||
|
Enzo Biochem
ENZ
|
841 K | - | -8.98 % | $ 14.8 K | ||
|
Lantheus Holdings
LNTH
|
3.8 M | $ 76.1 | 0.53 % | $ 5.14 B | ||
|
Biocept
BIOC
|
518 K | - | -13.05 % | $ 7.29 M | ||
|
Medpace Holdings
MEDP
|
23.2 M | $ 498.34 | 1.81 % | $ 14.4 B | ||
|
Heska Corporation
HSKA
|
2.94 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
475 K | - | -20.0 % | $ 1.06 M | ||
|
Interpace Biosciences
IDXG
|
431 K | $ 1.96 | 5.82 % | $ 8.67 M | ||
|
Mettler-Toledo International
MTD
|
35.1 M | $ 1 259.94 | -1.11 % | $ 26 B | ||
|
ICON Public Limited Company
ICLR
|
24.3 M | $ 114.19 | 2.49 % | $ 9.42 B | ||
|
IDEXX Laboratories
IDXX
|
27.1 M | $ 569.55 | 0.87 % | $ 45.8 B | ||
|
Neogen Corporation
NEOG
|
5.64 M | $ 9.41 | 0.21 % | $ 2.04 B | ||
|
Illumina
ILMN
|
79 M | $ 127.38 | 0.59 % | $ 20.3 B | ||
|
IQVIA Holdings
IQV
|
93 M | $ 173.26 | 0.5 % | $ 29.8 B | ||
|
Pacific Biosciences of California
PACB
|
448 K | $ 1.34 | -0.74 % | $ 402 M | ||
|
Koninklijke Philips N.V.
PHG
|
241 M | $ 27.11 | -0.66 % | $ 20 B | ||
|
QIAGEN N.V.
QGEN
|
23.4 M | - | - | $ 10.6 B | ||
|
Motus GI Holdings
MOTS
|
169 K | - | -34.28 % | $ 263 K | ||
|
Chembio Diagnostics
CEMI
|
915 K | - | 0.22 % | $ 16.8 M | ||
|
Laboratory Corporation of America Holdings
LH
|
191 M | $ 273.72 | 0.36 % | $ 22.8 B | ||
|
Myriad Genetics
MYGN
|
6.9 M | $ 4.75 | 3.49 % | $ 440 M | ||
|
Sotera Health Company
SHC
|
5.76 M | $ 14.96 | 0.61 % | $ 4.25 B | ||
|
NeoGenomics
NEO
|
4.78 M | $ 8.0 | 3.23 % | $ 1.02 B | ||
|
National Research Corporation
NRC
|
451 K | $ 17.16 | -1.04 % | $ 384 M |